The discovery of liver kinase B1 (LKB1) as an upstream kinase for AMP-activated protein kinase (AMPK) led to the identification of several related kinases that also rely on LKB1 for their catalytic activity. Among these, the salt-inducible kinases (SIKs) have emerged as key regulators of metabolism. Unlike AMPK, SIKs do not respond to nucleotides, but their function is regulated by extracellular signals, such as hormones, through complex LKB1-independent mechanisms. While AMPK acts on multiple targets, including metabolic enzymes, to maintain cellular ATP levels, SIKs primarily regulate gene expression, by acting on transcriptional regulators, such as the cAMP response element-binding protein-regulated transcription coactivators and class IIa histone deacetylases. This review describes the development of research on SIKs, from their discovery to the most recent findings on metabolic regulation.
Salt-inducible kinases (SIKs) are related to AMP-activated protein kinase (AMPK), but do not appear to be involved in the sensing and regulation of cellular energy levels.
SIKs and other AMPK-related kinases all require phosphorylation of their kinase domain T-loop to be active. Unlike AMPK however, SIKs are constitutively T-loop phosphorylated and their intrinsic kinase activity is thus rarely regulated in response to extracellular signals. SIKs are however phosphorylated, for example, by PKA, outside the kinase domain, leading to changes in their cellular function.
SIK activity is strictly required for the inhibition of glucose production in mouse liver; however, the contribution of different SIK isoforms to this function in vivo is not yet clear.
SIK2 is downregulated in adipose tissue from obese and insulin-resistant individuals and might contribute to reduced insulin sensitivity and glucose uptake in adipocytes during obesity.
Molecular Targets and Metabolic Functions of SIKs
Emerging Role of CRTCs as Key Targets of SIKs A key discovery in unraveling the mechanistic basis for inhibition of CREB by SIKs and further linking these kinases to the regulation of metabolism was made by Screaton and colleagues, who in 2004 identified CRTC2 as a direct substrate for SIKs [9] . They found that CRTC2 accumulates in the cytoplasm of resting pancreatic b-cells but rapidly translocates to the nucleus upon simultaneous treatment with cAMP-and Ca 2+ -elevating stimuli. Mass spectrometry analysis allowed identification of residues within CRTC2 that are phosphorylated in resting cells, but become dephosphorylated when cellular cAMP levels are elevated. Ser171 was proposed to be the primary phosphorylation site mediating interaction of CRTC2 with 14-3-3 proteins, which sequester CRTC2 in the cytoplasm under resting conditions [9] . In response to cAMP-and Ca 2+ signals, CRTC2 (Ser171) becomes dephosphorylated, and CRTC2 accumulates in the nucleus where it cooperates with CREB to drive transcription. Mass spectrometry analysis on cytoplasmic CRTC2 revealed the presence of SIK2 and suggested that SIK2 is the inhibitory kinase that maintains CRTC2 in latent cytoplasmic complexes. SIK1 had previously been identified as a modulator of CREB-dependent transcription in adrenocortical carcinoma cells [11] ; however, the underlying molecular mechanism remained elusive. The discovery of the link between CRTCs and SIKs opened a new area of investigation that uncovered complex regulation of CRTC2 activity by multiple post-translational modifications under normal and pathophysiologic states and prompted deeper investigation into the metabolic roles of SIKs.
Pancreatic b-Cells
Regulation of CRTC2 and CREB by LKB1/SIKs in b-Cells In pancreatic b-cells, CREB is known to control gene expression important for the increase in b-cell function and mass induced by glucose and incretins [27] . Growing evidence also points to an important role for CRTC2 in promoting glucose-induced insulin secretion and b-cell survival [9, [27] [28] [29] . Subsequent to their discovery that dephosphorylation of CRTC2 on Ser171 contributes to cAMP-and Ca 2+ -induced activation of CREB in b-cells [9] , Screaton et al. reported that CRTC2 may also mediate effects of glucose on CREB activity [29] . They identified an additional key Glossary 14-3-3 proteins: cytosolic scaffolding proteins that bind sequence motifs containing phosphorylated serine or threonine residues. They have multiple functions but commonly act to anchor their targets, for example, gene regulatory proteins, in the cytosol. Adipogenesis: the maturation of precursor cells into lipid storing, insulin-sensitive adipocytes. AMP-activated protein kinase (AMPK): a key energy sensor that by binding adenine nucleotides (ATP, ADP, and AMP), monitors and subsequently regulates and maintains cellular energy levels. It does so by stimulation of ATPgenerating and inhibition of ATPconsuming pathways. AMPK-related kinases: a family of kinases with sequence homology to AMPK in their activation loop. Like AMPK, their catalytic activity depends on phosphorylation by the common upstream kinase LKB1. cAMP: a second messenger that mediates diverse effects of hormones (e.g., glucagon and catecholamines). cAMP response element-binding protein (CREB): a transcription factor that, upon cAMP elevation, binds to cAMP response elements in gene promoters, thereby regulating expression. CREB-regulated transcriptional coactivators (CRTCs): a family of coactivators (CRTC1, CRTC2, and CRTC3) that, when dephosphorylated, translocate to the nucleus, bind to CREB, and activate CREB-mediated gene expression. Gluconeogenesis: the process in which glucose is generated de novo from various substrates such as glycerol, lactate, pyruvate, and alanine, for example, during fasting. Gluconeogenesis mainly takes place in the liver and is activated and inhibited in response to glucagon and insulin, respectively. HDAC 4/5/7: so-called class IIa HDACs. They appear not to possess any deacetylase activity on their own but are believed to cooperate with other HDAC isoforms to regulate the acetylation status of different targets.
Box 1. Discovery of SIKs
During 1999-2000, Sik was identified as a gene that is rapidly induced in response to various stimuli in different cell types. Upon identification of additional isoforms, this gene and its gene product were later denoted Sik1. For clarification, the first SIK isoform to be identified is termed SIK1 throughout this review article. Wang et al. [4] sought to identify factors that regulate function of the adrenal cortex in response to changes in plasma Na + /K + balance and screened genes that were induced in rat adrenal gland following a Na + -or K + -enriched diet. A novel cDNA clone, termed salt-inducible kinase (Sik), encoding a 776-amino acid polypeptide with substantial similarity to the AMPK/sucrose nonfermenting kinase (SNF1, the yeast homolog of mammalian AMPK) family, emerged from the screen. They also found that Sik1 mRNA expression is rapidly stimulated by adrenocorticotropic hormone in mouse and rat adrenal cells. Feldman et al. [5] were searching for genes in neuronal cells that were preferentially induced by membrane depolarization. They identified a gene product that is induced by potassium, forskolin, or a calcium ionophore and hence termed it KID-2 (kinase-induced by depolarization-2). Xia et al. [6] were studying the role of Qin, a gene shown to induce oncogenic transformation, and sought to identify genes that were differentially expressed in chicken embryo fibroblasts transformed by Qin. One of the up-regulated Qin targets identified was a protein kinase termed QIK (Qin-induced kinase) that displayed high homology to SIK1 cloned by Wang et al. [4] just before their publication. It should also be noted that in 1994, Ruiz and colleagues [7] had also identified a putative serine/threonine kinase most similar to SNF1, named myocardial SNF-like kinase (msk).
Identification of Sik1 prompted Okamoto and colleagues to search for its closely related genes. Analysis of human and mouse genomic databases led them to identify such genes, which they termed Sik2 and Sik3 [8, 9] . The Sik1 gene is located on human chromosome 21, whereas both Sik2 and Sik3 genes are localized on chromosome 11. SIKs are evolutionary conserved; Drosophila melanogaster and Caenorhabditis elegans both have SIK homologs, termed dSIK and Kin-29, respectively [13] [14] [15] [16] . phosphorylation site on CRTC2, Ser275, that also mediates 14-3-3 binding and cytosolic retention of CRTC2 and that was dephosphorylated in response to glucose. The AMPK-related kinase MARK2 was proposed to be the upstream kinase responsible for Ser275 phosphorylation. Identifying which phosphorylation sites and kinases that are predominantly responsible for CRTC2 regulation has proved challenging. Using a b-cell-specific SIK2 knockout mouse model, the Screaton group demonstrated that SIK2 was in fact fully dispensable for phosphorylation of CRTC2 in mouse islets [30] . However, pharmacological inhibition of all three SIK isoforms was shown to attenuate the phosphorylation of CRTC1 in clonal b-cells and islets [31] . Collectively, these results support that SIKs indeed regulate CRTC phosphorylation but that different SIKs (or other AMPK-related kinases) can compensate for the absence of one isoform.
b-Cell Function in SIK Knockout Mouse Models
More recently, two studies have directly investigated the function of SIK1 and SIK2 in islets and report contrasting roles for these SIK isoforms in the regulation of insulin secretion [30, 32] ( Figure 1 ). They also demonstrate an increase and a reduction, respectively, when analyzing insulin secretion from islets treated with the pan-SIK inhibitor HG-9-91-01 (Box 3).
Sakamaki et al. generated mice lacking SIK2 specifically in b-cells [30] . These mice do not phenocopy LKB1 loss, which was shown to result in elevated insulin secretion due to an increase in b-cell mass [38] [39] [40] , but instead they display reduced glucose-stimulated insulin secretion and impaired glucose tolerance, with no changes in b-cell mass or survival. The mechanism whereby SIK2 stimulates insulin secretion was shown to involve SIK2-mediated phosphorylation of the cyclin-dependent protein kinase 5 (CDK5) activator p35 and subsequent reduced phosphorylation of a voltage-dependent calcium channel, leading to increased Ca 2+ influx and insulin secretion ( Figure 2 ). Furthermore, they reported that SIK2 protein levels were elevated in response to high glucose and in animal models of pre-diabetes, whereas this induction of SIK2 was abolished in diabetic mice [30] . This raises the possibility that SIK2 is involved in b-cell compensation during hyperglycemia and that loss of SIK2 could contribute to b-cell failure and diabetes. In future work, it would be important to verify whether the SIK2-p35 signaling plays a role in human b-cells, and it would also be of interest to study whether this signaling axis is relevant in other cells/tissues. Moreover, identifying mechanisms whereby SIK2 protein is elevated in response to high levels of glucose and exploring why this effect is undetectable under diabetic conditions would be of major significance.
In contrast to b-cell-specific SIK2 knockout mice, Kim et al. reported that global deficiency in SIK1 resulted in improved glucose tolerance and increased plasma insulin levels during a glucose tolerance test in mice [32] . Further analysis revealed that SIK1 deficiency resulted in elevated firstand second-phase insulin secretion without changes in total insulin content. To identify mechanisms for those metabolic phenotypes, Kim et al. mapped an optimal SIK1 consensus sequence using randomly mutated peptides encompassing amino acids 164-177 of CRTC2 [32] . Using this
, phosphodiesterase 4D (PDE4D) was identified as a candidate substrate, which was proposed to mediate effects of SIK1 in b-cells ( Figure 1 ). This conclusion was based on the ability of SIK1 to phosphorylate PDE4D on Ser136 and Ser141 in vitro, the inability of S136A/S141A mutant PDE4D to reduce cAMP levels in forskolin-treated cells, and the lack of inhibition of insulin secretion when SIK1 was overexpressed in b-cells in which PDE4D was simultaneously inhibited or silenced. Intriguingly, a recent study has demonstrated that AMPK antagonizes hepatic glucagon signaling (cAMP-PKA) via phosphorylation-induced PDE4B activation [41] . Given that AMPK and SIKs broadly share consensus phosphorylation motif and SIK1 phosphorylates PDE4D [32] , it would be of interest to see if SIK isoforms regulate PDE4B and glucagon signaling in the liver.
Kim et al. also analyzed islets derived from SIK2 global knockout mice and wild-type islets treated with the SIK inhibitor HG-9-91-01. In both cases, they found that insulin secretion was enhanced, compared to control islets [32] . These data are in sharp contrast to what was reported by the Screaton group, who instead used b-cell-specific SIK2 knockout islets, but the same SIK inhibitor [30] . It should be noted that in islets derived from SIK1 and SIK2 global knockout mice, the lack of SIK1/2 in other islet cells (non-b-cells) might also contribute to the observed level of insulin secretion. Thus, the global models are not necessarily informative Box 
Structure and Regulation of SIKs by Phosphorylation
All three SIK isoforms share a highly homologous N-terminal kinase domain, but C-terminal regions are less conserved and differ in length ( Figure I ). SIK isoforms also possess a ubiquitin-associated domain ( Figure I ) that appears to play a role in allowing SIKs (and other AMPK-related kinases) to be activated by LKB1 [17, 18] .
Phosphorylation of the Kinase Domain by LKB1
Like other AMPK-related kinases, SIKs are phosphorylated by LKB1 on a highly conserved threonine residue (homologous to Thr172 in AMPK) in their activation loop [1, 17] . This phosphorylation is essential for their catalytic activity, but not known to be affected in response to external stimuli or by low cellular energy conditions [1, 19] like AMPK. The most widely received model is that LKB1 is constitutively active; therefore, its dependent kinases (except AMPK) are also constitutively phosphorylated (on the activation loop) and active in cells.
Phosphorylation Outside of the Kinase Domain in Response to Metabolic Cues
Multiple studies have shown that SIKs are phosphorylated at a C-terminal serine residue (SIK1, Ser577; SIK2, Ser587; SIK3, Ser551) in response to agents that elevate intracellular cAMP levels and thus activate protein kinase A (PKA) [10, [20] [21] [22] [23] . Detailed studies of glucagon-and catecholamine-induced phosphorylation of SIK2 have been performed in hepatocytes and adipocytes, respectively, and these studies report additional PKA phosphorylation sites (Ser343, Ser358, Thr484, and Ser587) [20, 21] . A large body of evidence indicates that cAMP-induced phosphorylation serves to restrict SIK cellular activity [9, 10, 24, 25] , however with mechanisms that differ between SIK isoforms and that in several aspects remain unclear. Rather than a change in intrinsic activity, altered substrate availability is likely involved. Indeed, SIK1 undergoes phosphorylation-dependent nucleocytoplasmic shuttling [10] . Moreover, the phosphorylation of SIK2 and SIK3 was shown to induce their binding to 14-3-3 proteins, which coincides with reduced substrate binding [20, 22, 26] . Identifying the exact mechanisms involved in cAMP-induced modulation of SIKs and subsequent biological actions represents a key future challenge.
Dentin et al. reported that in hepatocytes, insulin promotes SIK2 phosphorylation on Ser358 and that this results in stimulation of SIK2 activity measured in vitro [24] . However, these observations have been challenged by more recent studies that found no phosphorylation of Ser358 in response to insulin, and no effect of cAMPinduction or insulin on the in vitro activity of SIK2 [20, 21] . The effect of feeding signals on SIK function thus remains controversial (see 'Liver'). 2) used by some groups [22, 51, 72] , are shown within parentheses. UBA, ubiquitin-associated domain.
about the specific role of SIKs in b-cells, and results are likely to differ from those obtained in islets, with b-cell-specific SIK2 loss. Clarifying the effect that global and isoform-specific SIK loss/inhibition has on islet function, mass, and survival, using alternative approaches, for example additional b-cell specific and/or inducible mouse models or isoform-selective inhibitors would be of great interest for future studies.
Liver
The SIK/CRTC/HDAC Pathway and the Regulation of Gluconeogenesis CRTC2 was reported to play a key role in fasting-induced hepatic gluconeogenesis based on the following observations: (i) CRTC2 was enriched in the nuclei of hepatocytes during fasting or after exposure to cAMP-raising agents/hormones; and (ii) overexpression of CRTC2 in the liver promoted gluconeogenesis, whereas RNAi-mediated silencing of CRTC2 resulted in the opposite effect [42, 43] . The observation that CRTC2 subcellular localization was regulated via cAMP-dependent signaling in hepatocytes was reminiscent of what was observed in b-cells [9] and altered expression levels/activity of SIKs modulated the phosphorylation status and subcellular localization of CRTC2 [21, 24, 42] . Indeed, overexpression of SIK1 in primary hepatocytes was associated with enhanced CRTC2 phosphorylation on Ser171, resulting in suppression of a forskolin-or cAMP-induced increase in Pck1 gene expression [42] . This suppression was rescued when a CRTC2 S171A mutant was introduced. However, it can be noted that recent work using liver-specific knockout concluded that liver SIK1 is not required for regulation of CRTC2 and gluconeogenesis in vivo [44] . A subsequent study from the Montminy group showed that SIK2, but not SIK1, also plays an important role during feeding and insulinmediated suppression of gluconeogenesis [24] . Dentin et al. showed that refeeding following fasting promoted hepatic CRTC2 Ser171 phosphorylation, nuclear export, and proteasomal degradation, which was associated with suppression of hepatic gluconeogenic gene expression. This refeeding-mediated increase in CRTC2 phosphorylation was thought to be due to an increase in the kinase activity of SIK2 by Akt2-mediated phosphorylation on Ser358 [24] . Taken together, this study implicated that SIK2 functions as a master signaling switch controlling fasting/glucagon and feeding/insulin effects on the regulation of gluconeogenic gene expression by CRTC2-CREB [12] . In 2011, two papers together suggested that AMPK-related kinases, including SIK isoforms, might also regulate gluconeogenesis through class IIa HDACs (HDAC 4/5/7) [45, 46] .
In sharp contrast to the mechanism proposed by Dentin et al., a recent study provided evidence that insulin does not promote phosphorylation or activation of SIK2 in the liver [21] . Moreover, two independent groups studied SIK2-deficient hepatocytes and showed that genetic inactivation of SIK2 has no impact on fasting-and feeding-mediated changes in gluconeogenic gene expression and blood glucose levels in vivo [21, 47] . However interestingly, the pan-SIK inhibitor HG-9-91-01 promoted dephosphorylation of CRTC2/3 and HDAC4, resulting in enhanced gluconeogenic gene expression and glucose production in hepatocytes (Figure 2 ), an effect that was abolished when either an inhibitor-insensitive mutant SIK was introduced or LKB1 was genetically ablated [21] . This demonstrated that the LKB1-SIK pathway indeed acts as a gluconeogenic suppressor in the liver but that the SIK2 isoform alone does not play a major role. It also demonstrated that the pathway does not act solely via CRTC2/CREB but through Box 
Pharmacological Inhibition of SIKs
In 2012, Clark et al. described several pan-SIK inhibitors that they used to demonstrate a role for SIKs in the interconversion of classically activated and regulatory macrophages [33] . The most selective and potent of these compounds was HG-9-91-01. HG-9-91-01inhibited SIK isoforms, with an IC 50 value of 0.92, 6.6, and 9.6 nM for SIK1, SIK2, and SIK3, respectively, whereas the IC 50 values for other AMPK-related kinases, or for LKB1, were 100-to 1000-fold higher. The selectivity of HG-9-91-01 was tested using a panel of 108 different kinases, and in addition to SIK isoforms, the tyrosine kinases Src, YES1, and the Ephrin receptors EPH-A1 and EPH-A4 were inhibited to a significant degree (10% of the activity remaining when assayed in the presence of 0.1 mM HG-9-91-01). HG-9-91-01 not only targets the ATP-binding site but also an adjacent hydrophobic pocket created by a small so-called gatekeeper amino acid residue present in these kinases. By substituting this residue, Clark et al. generated an inhibitor-insensitive SIK mutant that was subsequently used to demonstrate that the action of HG-9-91-01 on gluconeogenesis in the liver is SIK dependent [21] .
Additional well-characterized SIK inhibitors include the potent ARN-3236 that has a preference for SIK2 (IC 50 < 1 nM versus 21.6 and 6.6 nM for SIK1 and SIK3, respectively) [34, 35] and the less potent YKL-05-093 [36] and its analog YKL-05-099, the latter of which has properties suitable for in vivo use [37] .
Although HG-9-91-01, YKL-05-099, and ARN-3236 have slightly different selectivity profiles, they have in common that they all inhibit Src family kinases. It is thus imperative to complement the use of these inhibitors with alternative approaches such as genetic modulation and/or the use of inhibitor-insensitive mutants.
multiple transcriptional regulators, as illustrated in Figure 2 and described recently [48] [49] [50] . To determine whether there is a predominant SIK isoform regulating the hepatic gluconeogenic program, Itoh et al. analyzed mouse primary hepatocytes lacking individual isoforms [51] . They observed that SIK3, but not SIK1 or SIK2, knockout hepatocytes showed a higher rate of basal and forskolin-induced glucose production. Consistent with these observations, SIK3 knockout hepatocytes displayed elevated expression of gluconeogenic genes as well as pronounced dephosphorylation of CRTC2 [51] . Collectively, it is evident that the LKB1-SIK pathway functions as a key gluconeogenic gatekeeper in the liver; however, whether it plays an important role in modulating hormone-mediated gluconeogenesis through CRTCs is controversial. Indeed, it has been reported that glucagon promotes mobilization of Ca 2+ through phosphorylation of the inositol 1,4,5-trisphosphate receptor. This, in turn, activates calcineurin (also known as protein phosphatase 2B), leading to dephosphorylation and nuclear translocation of CRTCs and a resultant activation of CREB-regulated gluconeogenic genes in hepatocytes [52] .
SIKs and Hepatic Lipid Metabolism
Both SIK1 and SIK2 have been proposed to be involved in hepatic lipogenesis, albeit with different mechanisms. Yoon et al. performed microarray analysis and noticed that modulation of SIK1 levels not only alters gluconeogenic [42] but also lipogenic gene expression in mouse liver [53] . They showed that silencing of SIK1 resulted in upregulated expression of genes involved in lipogenesis, whereas overexpression caused downregulation of those genes. They hypothesized that SIK1 inhibits the lipogenic gene program via regulation of Sterol regulatory element-binding protein 1c (SREBP-1c) . Indeed, Yoon et al. identified candidate SIK1 phosphorylation sites in SREBP-1c based on the proposed SIK-consensus motif [9] and, using cellfree assays, reported that SIK1 most likely phosphorylates three sites, namely, Ser265, Ser266, and Ser329. However, Yoon et al. did not show phosphorylation of endogenous SREBP-1c (on SIK1 sites); thus, it has not been shown whether SREBP-1c is indeed a bona fide substrate of SIK1. AMPK has also been shown to promote SREBP-1c phosphorylation at a distinct site (Ser372), which suppresses SREBP-1c nuclear localization and represses SREBP-1c target gene expression in hepatocytes [54] . It would be important to verify SIK1-dependent phosphorylation of endogenous SREBP-1c and confirm its role in hepatic lipogenesis by alternative models such as loss of function (i.e., SIK1 knockout).
Bricambert et al. showed that, similar to SIK1, silencing of SIK2 in mouse liver also causes increased expression of lipogenic genes, which was associated with hepatic steatosis [55] . They showed that SIK2 inhibited the histone acetyltransferase (HAT) p300 via direct phosphorylation on Ser89. This resulted in reduced acetylation of carbohydrate response element-binding protein, which resulted in decreased transcriptional activity on lipogenic genes [55] . Contrary to these observations, total SIK2 knockout mice showed normal levels of hepatic triglycerides and maintained normal adiposity/fat mass [47] . Liver-specific SIK2 knockout mice showed normal profiles in fasting-feeding mediated expression of lipogenic genes [21] . Whether chronic deletion of SIK2 has produced compensatory effects mediated by other SIK isoforms or mechanism(s) is unknown; however, off-target effects of SIK2 silencing might equally be responsible for the observed metabolic phenotypes in the study by Bricambert et al. [55] .
Uebi et al. reported that global SIK3 knockout mice display a lipodystrophic phenotype with altered cholesterol and bile acid metabolism in the liver [56] . However, it should be noted that majority (90%) of SIK3 -/-mice die 1 day after birth and surviving mice exhibit severe skeletal abnormalities and dwarfism [57] . It will be of interest to examine the role that SIK3 plays in lipid metabolism by using conditional knockout mouse models. Nonetheless, potential involvement of SIK3 in metabolic regulation is implicated in human studies; an SNP in the SIK3 gene was associated with higher triglyceride levels in an Asian-Indian cohort [58] and another study using a cross-population allele screen before genome-wide association study, has identified SIK3 as one of a few genes that display significant association with dyslipidemia or obesity in Amerindians [59] . Finally, genetic studies using Drosophila as a model system have demonstrated that the LKB1-SIK3 axis plays a key role in promoting lipid storage, by suppressing the activity of HDAC4 and the transcription factor FOXO, and subsequently the expression of brummer, the fly homolog of adipose triglyceride lipase [16, 46] . Taken together, although SIKs have been proposed to be involved as key mediators in regulation of hepatic lipid metabolism, it is unclear how and to what degree they are involved and under which physiological context. Adipose Tissue SIK2 is much more abundant in white-and brown adipose compared to other tissues, and among the three isoforms, SIK2 is the most prominent both in rodent and human adipocytes [8, 60] . It has also been reported that expression of SIK2 is robustly up-regulated during adipogenesis [8, 61, 62] . Based on these observations, studies of SIK signaling in adipocytes have mainly been focused on the SIK2 isoform.
A Role for SIK2 in the Regulation of Insulin Signaling? An early study by Horike et al. implicated that SIK2 plays a role in attenuating insulin signaling [8] . They reported that SIK2 phosphorylates IRS-1 on Ser789 (mouse)/Ser794 (human) in vitro and also in cultured adipocytes when SIK2 was ectopically overexpressed. Moreover, they observed that SIK2 activity was higher in white adipose tissue from diabetic db/db compared to control mice. These findings led Horike et al. to propose that SIK2-mediated IRS-1 phosphorylation contributes to the development of insulin resistance through inhibition of insulin signaling. In contrast, SIK2 expression was shown to be markedly reduced in adipose tissue and adipocytes from human individuals with obesity [60] . Moreover, although they did not specifically assess phosphorylation of IRS-1 on Ser789, recent studies in which SIK2 was suppressed in adipocytes using pharmacological inhibition or genetic silencing, do not support a negative role for SIK2 in insulin signaling [26, 47, 60] . Instead, global SIK2 knockout mice displayed reduced insulin-induced phosphorylation of protein kinase B (PKB)/Akt in adipose tissue [47] , and the same was true in human adipocytes treated with the SIK inhibitor HG-9-91-01 [60] . It should be noted that AMPK has been shown to phosphorylate the same site [Ser789 (mouse)/Ser794 (human)] on IRS-1 in vitro, but pharmacological activation of AMPK by AICAR in C2C12 muscle cells resulted in increased insulin signaling via enhanced association of IRS-1 with phosphatidylinositol 3-kinase [63] . Taken together, the available data rather support that SIK2 promotes insulin signaling in adipocytes, but the underlying mechanisms remain to be identified ( Figure 3 ).
Inhibition of Lipogenic Gene Expression and Promotion of Glucose Uptake
In 2008, Du et al. published one of the first studies that directly addressed the metabolic function of SIK2 in adipocytes [61] . By modulating SIK2 levels in 3T3L1 adipocytes, they demonstrated that SIK2 inhibits mRNA expression of lipogenic genes, including fatty acid synthase, acetyl-CoA carboxylase 2, and stearoyl-CoA desaturase 1 (Figure 3) , results that are reminiscent of the effect of SIK1 and SIK2 silencing in the liver [53, 55] . The molecular target(s) of SIK2 mediating this effect was not identified; however, based on its ability to rescue SIK2-mediated inhibition of FAS expression, the master lipogenic transcription factor SREBP-1c was proposed to be involved [61] . Interestingly, SREBP-1c is phosphorylated by SIK1 in vitro and was suggested as a substrate of SIK1 in the liver [53] .
In 2014, Park et al. reported the first metabolic characterization of global SIK2 knockout mice [47] . These mice had normal body weight; however, they were mildly glucose and insulin intolerant [47] . Multiple abnormalities in adipose tissue and adipocytes were reported, including enhanced forskolin-induced lipolysis, lipogenic gene expression, adipocyte size and macrophage infiltration and reduced adiponectin and Glut4 mRNA expression. The mechanism was proposed to be activation of CRTC2 and CREB, which was previously demonstrated to reduce GLUT4 and adiponectin expression via induction of the transcription factor ATF3 [64] (Figure 3 ). ATF3 was indeed up-regulated in adipose tissue of SIK2 knockout mice. However, none of the phenotypes reported by Park et al. were replicated when they silenced SIK2 in 3T3L1 adipocytes, arguing against CREB activation and ATF3 induction as the primary mechanism underlying the adipocyte phenotype of SIK2 knockout mice. The authors also demonstrated that pre-adipocytes isolated from the mice differentiated more readily than cells derived from wild-type mice. This raises the possibility that some of the observed effects on lipid metabolism are secondary to an increased differentiation state of pre-adipocytes in mice lacking SIK2. In future studies, it would be of interest to further explore this possibility and the molecular mechanism/primary target involved, for example, by analyzing the expression of adipogenic transcription factors in pre-adipocytes from SIK2 knockout mice. Also, to avoid any potential confounding effects that SIK2 might have on adipocyte differentiation, it would be necessary to generate an inducible adipose-specific SIK2 knockout mouse model. Another study, by Henriksson et al., mainly focused on characterizing downstream molecular targets of SIK2 in adipocytes [26] . Using both genetic and pharmacological approaches, they demonstrated that HDAC4, CRTC2, and CRTC3 are cellular targets of SIK2 in both rodent and human adipocytes. Since both class IIa HDACs (4 and 5) and CREB have been shown to inhibit Glut4 The upregulation of lipogenic gene expression due to reduction or lack of SIK2 was associated with higher accumulation of triglycerides in adipocytes/adipose tissue. The molecular target(s) mediating the inhibitory effect of SIK2 on lipogenic genes is not known, but sterol regulatory element-binding proteins (SREBPs) have been proposed. SIK2 silencing or pharmacological inhibition leads to a reduction in glucose uptake in both rodent and human adipocytes. In rodents, the mechanism(s) includes positive effects of SIK2 on GLUT4 expression, whereas in human adipocytes, SIK silencing or inhibition did not affect GLUT expression, but reduced the activating phosphorylation of protein kinase B (PKB/Akt). The known substrates of SIK2 in adipocytes identified so far are CREB-regulated transcription coactivator (CRTC)2, CRTC3, and histone deacetylase (HDAC)4. These transcriptional regulators have been implicated in mediating the positive effects of SIK2 on GLUT4 expression observed in rodent cells. ACC2, acetyl-CoA carboxylase 2; CREB; cAMP response elementbinding protein; FAS, fatty acid synthase; SCD1, stearoyl-CoA desaturase-1.
mRNA expression in adipocytes [64, 65] , these authors also investigated the role that SIK2 plays in regulation of GLUT4 expression and glucose uptake. Consistent with observations in the SIK2 knockout mouse study [47] , they found that GLUT4 expression was reduced in SIK2-deficient adipocytes [26] . Moreover, pharmacological inhibition of SIK isoforms resulted in reduced glucose uptake in primary rat adipocytes.
SIK2 in Human Adipocytes
So far, very few studies have addressed the expression or role of SIK isoforms in humans. However, as discussed above, it was recently demonstrated that, in contrast to rodents [61] , Sik2 and Sik3 mRNA levels are markedly reduced in adipose tissue from obese individuals [60] and that Sik2 levels display a tight inverse correlation with insulin resistance. In line with the rodent data, silencing or inhibition of SIK isoforms in human adipocytes resulted in reduced basal and insulin-stimulated glucose uptake and blunted phosphorylation of Akt/PKB. However, unlike in rodent adipocytes, GLUT4 was not reduced by SIK inactivation in human adipocytes, and interestingly, glucose uptake was blunted already after 1 h of SIK inhibitor treatment. This raises the possibility that SIK2 promotes glucose uptake through a mechanism that does not rely on changes in gene expression.
Collectively, these lines of evidence suggest that SIK2 functions to maintain insulin sensitivity and glucose uptake and might be protective in the development of obesity-induced insulin resistance in humans. In future studies, it will be important to elucidate which specific or set of downstream targets of SIK2 that mediates its effects on glucose uptake. Moreover, since SIKs clearly control the activity of CRTCs and class II HDACs in adipocytes, another goal should be to identify the genes regulated downstream of SIK/CRTCs/HDACs in human adipocytes.
Concluding Remarks and Perspectives
A growing number of studies have demonstrated that SIKs play key roles in controlling metabolic signaling pathways in various cell and tissue types. Naturally, a key question is whether SIKs could be considered as drug targets for metabolic disorders, which is unclear and under debate. Activation of the SIKs is expected to elicit some beneficial metabolic outcomes such as inhibition of hepatic glucose production, increase in glucose uptake into adipocytes, and enhanced insulin secretion (through SIK2) in people with type 2 diabetes. However, whether it is feasible to 'activate' SIKs by pharmacological means [e.g., via mimicking phosphorylation or inhibiting yet to be identified phosphatase(s)] is unknown. Initially, it was proposed that insulin could activate hepatic SIK2 through Akt-dependent phosphorylation on Ser358 [24] ; however this has been challenged [20, 21] . LKB1 does indeed activate all three SIK isoforms through phosphorylation of a threonine residue in the activation loop of their kinase domain, but LKB1 is unlikely a good target as it activates not only SIKs but also AMPK and other AMPK-related kinases [2] . It should be stressed that even though SIK activity is not altered when measured in vitro (cell-free assay), the cellular activity of SIKs is regulated through phosphorylation upon an increase in concentration of cAMP. The mechanism(s) appears to include changes in subcellular localization and/or protein-protein interactions [20, 22] . This needs to be further studied, and it would be of interest to determine whether there is a specific upstream kinase/phosphatase that can be targeted to modulate cellular SIK activity.
In the current review, we focused on the role of SIKs in metabolic control, but SIKs have also been proposed to be involved in several other biological processes. Recently, it has been demonstrated that SIKs function as a key molecular switch whose inhibition reprograms macrophages to an anti-inflammatory phenotype [33, 34, 66] . Moreover, SIKs, in particular SIK2, have been implicated in cancer progression and metastasis [67, 68] that inhibit SIKs may have a potential for the treatment for inflammatory diseases and cancer and are under development for this purpose [35] . However, one limitation of this strategy could be that, based on studies linking SIKs with glucose and lipid metabolism as described in this review, it is anticipated that patients treated with SIK inhibitors would develop hyperglycemia/ insulin resistance and potentially type 2 diabetes. Intriguingly, it has recently been reported that the clinically approved cancer drugs bosutinib and dasatinib potently inhibit SIKs, leading to the transformation of macrophages to an anti-inflammatory phenotype [69] . Indeed, some clinical case studies have reported that patients suffering from chronic myeloid leukemia and type 2 diabetes show significant improvement in their glucose handling with dasatinib-based therapy [70, 71] . It could be argued that the beneficial effects of dasatinib on glycemic control/type 2 diabetes is due to its anti-inflammatory properties, since a growing body of literature has documented that the presence of proinflammatory macrophages in adipose tissue plays a causal role for the development of insulin resistance. However, given that bosutinib and dasatinib are developed for other targets, whether such effects are mainly mediated through SIKs is not known. Much larger and longitudinal trials will be necessary to evaluate the effects of these drugs on inflammation and metabolic responses. It would be of major interest to develop and test SIK inhibitors, possibly isoform-specific ones, to reveal acute and chronic effects of SIKs in vivo for metabolic and other functions.
